ArticlePatient preference and adherence2022

Patients' Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation.

José Esteban Costa Gil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.